Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Apixaban Versus Enoxaparin for Thromboprophylaxis After Joint Replacement Surgery: Pooled Analysis of Major Venous Thromboembolism and Bleeding In 8,464 Patients From the ADVANCE 2 and 3 Trials

Gary E. Raskob, Ph.D., Alexander S. Gallus, M.D., Graham F. Pineo, M.D., Dalei Chen, Ph.D., Luz Margarita Ramirez, M.D., Michael Rud Lassen, M.D.

Blood (2010) 116 (21): 192.

https://doi.org/10.1182/blood.V116.21.192.192

Published: 2010

Journal Articles

Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial

Michael Rud Lassen, MD, Alexander S Gallus, MD, Graham F Pineo, MD, Gary E Raskob, PhD, the ADVANCE-1 Investigators

Blood (2008) 112 (11): 31.

https://doi.org/10.1182/blood.V112.11.31.31

Published: 2008

Journal Articles

Is Differential Activity of Enoxaparin and Unfractionated Heparin According to the Location of Deep-Vein Thrombosis in Acute Ischemic Stroke Patients Driven by Different Pathogenic Mechanisms?.

Ludovic Drouet, David G. Sherman, Gregory W. Albers, Christopher Bladin, Cesare Fieschi, Alberto A. Gabbai, Carlos S. Kase, William O’Riordan, Graham F. Pineo

Blood (2007) 110 (11): 303.

https://doi.org/10.1182/blood.V110.11.303.303

Published: 2007

Journal Articles

Prevention of Venous Thromboembolism after Acute Ischemic Stroke with Enoxaparin Versus Unfractionated Heparin and the Impact of Stroke Severity.

David G. Sherman, MD, Gregory W. Albers, MD, Christopher Bladin, MD, Min Chen, MS, Cesare Fieschi, MD, Alberto A. Gabbai, MD, Carlos S. Kase, MD, William O’Riordan, MD, Graham F. Pineo, MD, for the PREVAIL Investigators

Blood (2006) 108 (11): 713.

https://doi.org/10.1182/blood.V108.11.713.713

Published: 2006

Journal Articles

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy Compared with Usual-Care Anticoagulation for the Treatment of Patients with Proximal Venous Thrombosis: Harm Associated with Thrombocytopenia.

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F. Brant, PhD, for the LITE Trial Investigators

Blood (2005) 106 (11): 4142.

https://doi.org/10.1182/blood.V106.11.4142.4142

Published: 2005

Journal Articles

Self-Managed Long-Term Low-Molecular-Weight Heparin Compared with Usual-Care Anticoagulation for Patients with Proximal Venous Thrombosis: Harm Associated with Bleeding!.

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F. Brant, PhD, for the LITE Trial Investigators

Blood (2005) 106 (11): 901.

https://doi.org/10.1182/blood.V106.11.901.901

Published: 2005

NARROW

Apixaban Versus Enoxaparin for Thromboprophylaxis After Joint Replacement Surgery: Pooled Analysis of Major Venous Thromboembolism and Bleeding In 8,464 Patients From the ADVANCE 2 and 3 Trials

Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial

Is Differential Activity of Enoxaparin and Unfractionated Heparin According to the Location of Deep-Vein Thrombosis in Acute Ischemic Stroke Patients Driven by Different Pathogenic Mechanisms?.

Prevention of Venous Thromboembolism after Acute Ischemic Stroke with Enoxaparin Versus Unfractionated Heparin and the Impact of Stroke Severity.

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy Compared with Usual-Care Anticoagulation for the Treatment of Patients with Proximal Venous Thrombosis: Harm Associated with Thrombocytopenia.

Self-Managed Long-Term Low-Molecular-Weight Heparin Compared with Usual-Care Anticoagulation for Patients with Proximal Venous Thrombosis: Harm Associated with Bleeding!.

Email alerts

ASH Publications

American Society of Hematology

Apixaban Versus Enoxaparin for Thromboprophylaxis After Joint Replacement Surgery: Pooled Analysis of Major Venous Thromboembolism and Bleeding In 8,464 Patients From the ADVANCE 2 and 3 Trials

Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial

Is Differential Activity of Enoxaparin and Unfractionated Heparin According to the Location of Deep-Vein Thrombosis in Acute Ischemic Stroke Patients Driven by Different Pathogenic Mechanisms?.

Prevention of Venous Thromboembolism after Acute Ischemic Stroke with Enoxaparin Versus Unfractionated Heparin and the Impact of Stroke Severity.

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy Compared with Usual-Care Anticoagulation for the Treatment of Patients with Proximal Venous Thrombosis: Harm Associated with Thrombocytopenia.

Self-Managed Long-Term Low-Molecular-Weight Heparin Compared with Usual-Care Anticoagulation for Patients with Proximal Venous Thrombosis: Harm Associated with Bleeding!.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only